All Dr Jonas Helma-Smets (chief scientific officer and co-founder of Tubulis) articles
-
NewsNew Alco5 platform could advance cancer antibody therapies
Biotech company, Tubulis, has published preclinical data on its Alco5 antibody-drug conjugate platform, demonstrating the ability to link antibodies with previously inaccessible hydroxy-containing drugs.